Seeking Alpha

Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma...

Celgene's (CELG +1.6%) Abraxane breast cancer treatment for patients with metastatic melanoma met its primary endpoint of "progression-free survival" in a Phase III trial that compared the medicine with acarbazine chemotherapy. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|